Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.6004/jnccn.2015.0075 http://scihub22266oqcxt.onion/10.6004/jnccn.2015.0075 C4898052!4898052 !25964641     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25964641 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25964641 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Natl+Compr+Canc+Netw 2015 ; 13 (5 ): 554-86 Nephropedia Template TP {{tp|p=25964641 |t=2015. Hodgkin lymphoma, version 2 2015 |pdf=|usr=}}{{25964641 }} gab.com Text Hodgkin lymphoma, version 2 2015 JO: J Natl Compr Canc Netw http://www.kidney.de/pget.php?&tw=1&pmid=25964641 #FOAvip Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment. Twit Text FOAVip Hodgkin lymphoma, version 2 2015 ????J Natl Compr Canc Netw http://www.kidney.de/pget.php?&tw=1&pmid=25964641 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25964641 #FOAvip English Wikipedia <ref>{{Cite pmid|25964641 }}</ref> Hodgkin lymphoma, version 2 2015 #MMPMID25964641 Hoppe RT ; Advani RH ; Ai WZ ; Ambinder RF ; Aoun P ; Bello CM ; Benitez CM ; Bierman PJ ; Blum KA ; Chen R ; Dabaja B ; Forero A ; Gordon LI ; Hernandez-Ilizaliturri FJ ; Hochberg EP ; Huang J ; Johnston PB ; Khan N ; Maloney DG ; Mauch PM ; Metzger M ; Moore JO ; Morgan D ; Moskowitz CH ; Mulroney C ; Poppe M ; Rabinovitch R ; Seropian S ; Tsien C ; Winter JN ; Yahalom J ; Burns JL ; Sundar H J Natl Compr Canc Netw 2015[May]; 13 (5 ): 554-86 PMID25964641 show ga Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment. |Follow-Up Studies [MESH] |Hodgkin Disease/*diagnosis/*therapy [MESH] |Humans [MESH] |Neoplasm Staging [MESH] |Positron-Emission Tomography [MESH] |Prognosis [MESH]Hodgkin lymphoma, version 2 2015 (epmc).pdf DeepDyve Pubget Overpricing